The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.
Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.
Stephen Knight, whose nonprofit saves lives by providing foster care for dogs while their owners focus on addiction recovery, ...
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for treating cognitive symptoms in Parkinson’s disease, a condition currently ...
The study findings showed increased risks of dementia for anticholinergic drugs overall and specifically for the ...
A recent scientific study has issued warnings that certain commonly prescribed medications could elevate the risk of dementia ...
The singer, 50, revealed earlier this year that his mother Janet had been diagnosed with dementia, four-years after his ...
The funding comes from a county program that offers cash to businesses that want to expand locally and add at least 10 new ...
A decline in motor skills is a hallmark of Parkinson's disease, regularly taking the form of slowness, rigidity, and tremors.
MY LOW POINT came about eight years after my diagnosis. I was 35 years old, and weighed about 250 lbs., at 5’8”, and I had to ...
A research team led by Professor Cho Il-joo of the convergence medicine class at Korea University School of Medicine ...
Medtronic Percept neurostimulators send electrical signals through thin wires to specific brain regions affected by ...